Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02614508 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions

DRUG: Buparlisib
DRUG: Ibrutinib
BIOLOGICAL: Ofatumumab

Sponsor

Emory University

Collaborators

[object Object]